Find your next paid study

Children's National Research InstituteNCT07664176

~$10 – $5,625

Phase 2

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that…

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

National Cancer Institute (NCI)NCT07003295

~$10 – $5,625

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medicatio…

Michael J. Dennis, MDNCT05774899

~$10 – $7,500

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…

Northwestern UniversityNCT06410248

GlioblastomaRecurrent GlioblastomaGlioblastoma Multiforme of Brain

Pilot Study to Evaluate Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI Methods at 7Tesla Metabolic Profiling of Glioblastoma

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F…

Abramson Cancer Center at Penn MedicineNCT06613841

Phase 3

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are consid…

Endometrial CancerRecurrent or Progressive Endometrial Cancer

A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). The study aims to demons…

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Bicara TherapeuticsNCT07807163

~$10 – $8,750

Phase 2

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint Inhibitors

This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or…

Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma

Emory UniversityNCT05039073

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more

A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib …

M.D. Anderson Cancer CenterNCT05010122

Recurrent GliosarcomaRecurrent Supratentorial GlioblastomaSupratentorial Gliosarcoma

A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Grade 4 Astrocytoma (Glioblastoma)

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 an…

M.D. Anderson Cancer CenterNCT04991870

Phase 2

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azaci…

Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more

M.D. Anderson Cancer CenterNCT03383575

Neoplasms, BrainGlioblastoma MultiformeGlioblastoma of Cerebellum+30 more

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumo…